Hematological Disorders Market Landscape | Delveinsight
Wearable Devices: Weighing the Potential Benefits and Pitfalls of the Innovative Wearable Products
oncological-drugs-to-be-launch-in-2022
Most Promising Oncological Drugs Expe...

The innovation in the oncology drug pipeline has resulted in a record number of FDA and EU approvals in rec...

medtech-news-for-zynex-foldax-bd-ge-edwards
Sky Medical’s Geko™ device; Fi...

Sky receives FDA clearance to market the geko™ device for venous insufficiency and ischemia  On...

Diffuse Large B-cell Lymphoma Highlights
Major Highlights of Diffuse Large B-c...

ASH 2021,which ended on December 14, 2021, was a premier event in malignant and non-malignant hematology. L...

Follicular Lymphoma Highlights
Major Highlights of Follicular Lymphoma (FL) in ASH 2021

ASH 2021,which ended on December 14, 2021, was a premier event in malignant and non-malignant hematology. Like every year, key pharma players took center stage and shared new data regarding the de...


pharma-news-for-pfizer-takeda-novartis-roche
Pfizer to acquire Arena Pharma; Takeda’s ‘Wave 2’ multiple myeloma med data; No...

Pfizer acquires drugmaker Arena for USD 6.7 billion to address unmet needs Pfizer declared that it is acquiring Arena Pharmaceuticals, a drug company specializing in inflammation and immunology...


Myelodysplastic Syndrome Key Pharma Players
Myelodysplastic Syndromes (MDS): Key Pharma Players Unveiling Updated Findings at ASH 2021

There has been limited progress in the approval of novel agents in MDS. It has been a long wait since the last approval of lenalidomide (Revlimid) – only approved for 5–10% (del 5q) MDS patients –...


ash-2021-annual-meeting-coverage
Major Highlights of ASH 2021 Annual Meeting: Stay abreast of the fresh developments!!

Blood cancers have seen tremendous advancements in the past few years due to the dedication of researchers pulling out all the stops to churn out therapeutic innovations intended to be of service ...


pharma-news-for-bluebird-bio-fda-twist-bioscience-sosei-heptares
Bluebird bio may get gene therapy approved in the US; Neurocrine pens $2.6B pact with Sosei Hepta...

Bluebird bio may finally get a gene therapy approved in the US Bluebird bio may get gene therapy approved in the US. The Cambridge, MA biotech declared that the FDA had accepted and given prior...


Gene-Therapy-for-Hemophilia
The Evolved Gene Therapy for Hemophilia

Hemophilia is an inherited rare disorder where blood doesn’t clot in the regular way because the person affected doesn’t make enough blood-clotting proteins (clotting factors). Without these facto...


Editor's Pick
22 Healthcare Trends & Innovations to Watch in 2022 and Beyond

With the advent of new-age healthcare industry trends that are evident as of now, there...

Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021

Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did...

Analyzing the Key Trends Driving the Biosimilar Market Growth

The Biosimilars market is growing at a breakneck pace. The biosimilar market provides a...

CAR-T Cell Therapy aka Miraculous Technology: Mapping the Market, Approved Th...

Chimeric antigen receptor T-cell (CAR T) therapies are shown to have transformative pot...

Myelodysplastic Syndromes (MDS): Key Pharma Players Unveiling Updated Finding...

There has been limited progress in the approval of novel agents in MDS. It has been a l...